e-learning
resources
Milan 2017
Sunday, 10.09.2017
The spectrum of CTDs: from pathogenesis to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity
A. Rathnapala (Minuwangoda, Sri Lanka)
Source:
International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Session:
The spectrum of CTDs: from pathogenesis to treatment
Session type:
Thematic Poster
Number:
884
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Rathnapala (Minuwangoda, Sri Lanka). Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity. 884
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): clinical heterogeneity and outcome
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Verification of genetic associations with Scleroderma associated Interstitial Lung Disease
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Atypical variants of clinical course of sarcoidosis
Source: International Congress 2014 – ILDs 6
Year: 2014
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Familial pulmonary fibrosis: Clinical-functional and radiological features
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Castleman disease variant of atypical POEMS syndrome: A case presentatIon
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014
Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome
Source: International Congress 2014 – ILDs 1
Year: 2014
B-lymphocyte targeted therapy for patients with progressive fibrosing mediastinitis
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
The clinical features of 13 patients with interstitial pneumonia with positive anti-glycyl-tRNA synthetase autoantibodies
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Mutation alone does not predict the clinical course of surfactant protein C deficiency in children
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Comparison of physiological impairment in ILD patients with and without diagnostic IPF features
Source: International Congress 2014 – ILDs 4
Year: 2014
LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Early pulmonary phenotype in Hermansky-Pudlak syndrome: Analysis of the chILD-EU registry
Source: International Congress 2016 – Paediatric bronchology I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept